AD 2102
Alternative Names: AD-2102Latest Information Update: 28 Dec 2023
At a glance
- Originator Addpharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Hypertension(Combination therapy, In volunteers) in South Korea
- 28 Dec 2023 No recent reports of development identified for phase-I development in Hypertension(Monotherapy, In volunteers) in South Korea
- 30 Apr 2021 Addpharma completes a phase I clinical trials in Hypertension (In volunteers, Combination therapy) in South Korea (unspecified route) (NCT04600284)